Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Febrile Neutropenia 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Cytarabine 9fludarabine phosphate 8fludarabine 8Radiotherapy 7Vincristine 5Cyclosporine 5Whole-Body Irradiation 4Prednisone 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Etoposide 4Busulfan 4asparaginase erwinia chrysanthemi recombinant 3Tacrolimus 3Sirolimus 3Dasatinib 3Cord Blood Stem Cell Transplantation 3Bortezomib 3Asparaginase 3prednylidene 2pegaspargase 2ixazomib 2deltacortene 2blinatumomab 2Thiotepa 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Meropenem × Clear all
NCT05784844 2024-09-19

Antimicrobial Revision in Persistent Febrile Neutropenia

Wake Forest University Health Sciences

Phase 4 Withdrawn
Classical hematologyLymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡